

Datasheet: MCA2260

BATCH NUMBER 210115

Description:	RAT ANTI RITUXIMAB
Specificity:	RITUXIMAB
Other names:	MabThera [®] , Rituxan [®]
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	MB2A4
Isotype:	IgG2a
Quantity:	0.2 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			50 ug/ml
Immunohistology - Frozen			▪	
Immunohistology - Paraffin			▪	
ELISA	▪			5 ug/ml as coating antibody

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use

Product Form	Purified IgG - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution	TRIS buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	F(ab) ₂ fragment of Rituximab.

Fusion Partners	Spleen cells from immunised rats were fused with cells of the NS-1 mouse myeloma cell line.
Specificity	<p>Rat anti rituximab antibody, clone MB2A4, specifically recognizes the idiotypic determinants expressed by the rituximab chimeric monoclonal antibody. Rituximab is a therapeutic reagent directed against the human CD20 antigen expressed on the surface of B-cells.</p> <p>Rat anti rituximab antibody, clone MB2A4, is specific for rituximab and does not recognize other CD20 antibodies. Clone MB2A4 has been used in ELISA assays to monitor the levels of rituximab in patient serum following therapy (Cragg et al. 2004 and Hampson et al. 2010). Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line, however detection of rituximab bound <i>in vivo</i> to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the anti-rituximab antibody to cell bound rituximab (Beum et al. 2004).</p>
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells in 100ul.
ELISA	This product may be used in a direct ELISA or as a detection reagent, when conjugated to HRP, in a sandwich ELISA together with HCA186 as the capture reagent. Protocol: PK bridging ELISA to measure free drug
References	<ol style="list-style-type: none"> 1. Cragg, M. S. <i>et al.</i> (2004) A new anti-idiotypic antibody capable of binding rituximab on the surface of lymphoma cells. Blood. 104:2540-2 2. Cragg, M.S. <i>et al.</i> (2004) Apparent modulation of CD20 by rituximab: an alternative explanation. Blood. 103 (10): 3989-90; author reply 3990-1. 3. Beum, P.V. <i>et al.</i> (2004) Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. J Immunol Methods. 294 (1-2): 37-42. 4. Hampson, G. <i>et al.</i> (2010) Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. J Immunol Methods. 360 (1-2): 30-8. 5. Blasco, H. <i>et al.</i> (2007) Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods.325: 127-39. 6. Daydé, D. <i>et al.</i> (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 113: 3765-72. 7. Aung, T. <i>et al.</i> (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 108: 15336-41. 8. Schmidt, E. <i>et al.</i> (2009) Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 132: 334-41. 9. McDonald, V. <i>et al.</i> (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 8: 1201-8. 10. Kagan, L. <i>et al.</i> (2012) Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats. Pharm Res. 29: 490-499 11. Kagan, L. and Mager, D.E. (2013) Mechanisms of subcutaneous absorption of

- rituximab in rats. [Drug Metab Dispos. 41: 248-55.](#)
12. Liu, X.F. *et al.* (2012) Validation of a Gyrolab™ assay for quantification of rituximab in human serum. [J Pharmacol Toxicol Methods. 65: 107-14.](#)
13. Kagan, L. *et al.* (2014) Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. [Pharm Res. 31: 3265-73.](#)
14. Blasco, H. *et al.* (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. [Fundam Clin Pharmacol. 23: 601-8.](#)
15. Pers, J.O. *et al.* (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. [Arthritis Rheum. 56: 1464-77.](#)
16. Vacher, P. *et al.* (2015) Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. [J Immunol. pii: 1402942.](#)
17. Komori, M. *et al.* (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis [Annals of Clinical and Translational Neurology. Feb 1. \[Epub ahead of print\]](#)
18. Illidge, T.M. *et al.* (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. [Br J Haematol. Feb 5. \[Epub ahead of print\]](#)
19. Lioger, B. *et al.* (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. [Br J Clin Pharmacol. Feb 23. \[Epub ahead of print\]](#)

Storage	<p>Store at +4°C or at -20°C if preferred.</p> <p>This product should be stored undiluted.</p> <p>Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.</p>
Guarantee	18 months from date of despatch.
Acknowledgements	Rituxan® is a registered trademark of Biogen Idec/Genentech in the USA. MabThera® is a registered trademark of Roche in Europe
Health And Safety Information	<p>Material Safety Datasheet documentation available at: https://www.bio-rad-antibodies.com/SDS/MCA2260</p> <p>Material Safety Datasheet Documentation #10057 available at: https://www.bio-rad-antibodies.com/uploads/MSDS/10057.pdf</p>
Regulatory	For research purposes only

Related Products

Recommended Secondary Antibodies

Rabbit Anti Rat IgG (STAR20...) [RPE](#)

Rabbit Anti Rat IgG (STAR17...) [FITC](#)

Goat Anti Rat IgG (STAR69...) [FITC](#)

Goat Anti Rat IgG (STAR73...) [RPE](#)

Recommended Useful Reagents

[HUMAN ANTI RITUXIMAB \(HCA061\)](#)

[HUMAN ANTI RITUXIMAB \(HCA186\)](#)

Product inquiries: www.bio-rad-antibodies.com/technical-support

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M286259:160510'

Printed on 29 Jan 2026

© 2026 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)